It was just several years ago when Daiichi Sankyo Co., Ltd.’s first antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) was launched in the US, helped by the Japanese company’s largest collaborative deal ever at the time, with AstraZeneca PLC.
The ADC has been the firm’s mainstay since then, becoming a blockbuster on the back of its high efficacy in...






